Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Currently, there is no practical screening test for ovarian cancer in the general population. This stands in stark contrast to cervical cancer (Pap smears) or breast cancer (mammograms). Large-scale clinical trials, such as the UKCTOCS study, evaluated the use of Transvaginal Ultrasound (TVUS) and the blood biomarker CA-125 for screening asymptomatic women. Unfortunately, these studies failed to demonstrate a significant reduction in mortality.
The limitation of Transvaginal Ultrasound is its inability to distinguish reliably between benign and malignant masses in early stages, leading to many false positives and unnecessary surgeries. Furthermore, because high-grade serous carcinoma can originate in the fallopian tube and spread to the peritoneum while the ovary is still normal in size, ultrasound often misses the window of curability.
CA-125 (Cancer Antigen 125) is a protein found in the blood. While it is elevated in eighty percent of advanced ovarian cancers, it is elevated in only fifty percent of early-stage cancers. Moreover, it is non-specific; conditions like endometriosis, pregnancy, menstruation, and fibroids can all cause elevated CA-125. Therefore, it is not used as a standalone screening tool for the general public, though it is utilized in the surveillance of high-risk gene carriers.
When symptoms or a pelvic exam raise suspicion of ovarian cancer, the diagnostic workup begins with specialized imaging. A Transvaginal Ultrasound is typically the first-line test for assessing ovarian morphology. Features suggestive of malignancy include complex cysts with solid components, thick septations (walls within the cyst), and increased blood flow (Doppler flow) within the mass.
To evaluate the extent of disease, a Computed Tomography (CT) scan of the abdomen and pelvis with contrast is the standard. The CT scan looks for “omental cake” (thickening of the omentum), ascites, peritoneal implants on the liver or diaphragm, and enlarged lymph nodes. It provides the surgeon with a roadmap.
Magnetic Resonance Imaging (MRI) is utilized when the ultrasound is inconclusive, particularly to differentiate ovarian masses from uterine fibroids or to characterize indeterminate cysts. Positron Emission Tomography (PET-CT) is not always used for initial diagnosis, but it is valuable for detecting distant metastasis or for clarifying equivocal findings on a CT scan. The Risk of Malignancy Index (RMI) is a calculation that combines ultrasound score, menopausal status, and CA-125 level to triage patients to specialized oncology centers.
Beyond CA-125, newer biomarkers have been developed to improve diagnostic accuracy. Human Epididymis Protein 4 (HE4) is a biomarker less affected by benign conditions such as endometriosis than CA-125. It is instrumental in distinguishing benign from malignant masses in premenopausal women.
The ROMA (Risk of Ovarian Malignancy Algorithm) score combines CA-125 and HE4 levels with menopausal status to estimate the probability of malignancy. This score helps determine whether a patient should be managed by a general gynecologist (low risk) or referred to a gynecologic oncologist (high risk).
In the context of diagnosis, extracting fluid from the abdomen (paracentesis) or chest (thoracentesis) can provide cytological confirmation. However, if a pelvic mass is clearly resectable, doctors often avoid sticking a needle into it (biopsy) before surgery to prevent rupturing the capsule and spilling cancer cells into the abdomen. Diagnosis is typically confirmed intraoperatively (during surgery) by frozen-section analysis.
Ovarian cancer staging is surgical, meaning the final stage is determined by what the surgeon sees and removes during the operation. The International Federation of Gynecology and Obstetrics (FIGO) system is used.
Stage I: Cancer is limited to the ovaries or fallopian tubes. It is further divided into IA (one ovary), IB (both ovaries), and IC (capsule rupture or cancer on the surface).
Stage II: Cancer involves one or both ovaries with pelvic extension (to the uterus or fallopian tubes) or primary peritoneal cancer confined to the pelvis.
Stage III: Cancer has spread to the peritoneum outside the pelvis (upper abdomen) and/or to the retroperitoneal lymph nodes. This is the most common stage at diagnosis. It is subdivided by implant size: IIIA (microscopic), IIIB (visible < 2cm), and IIIC (visible > 2cm).
Stage IV: Distant metastasis. This includes fluid in the lining of the lungs (pleural effusion) with positive cancer cells (Stage IVA) or spread to the inside of the liver, spleen, or extra-abdominal organs (Stage IVB).
Accurate staging requires a systematic exploration of the abdomen, including biopsies of the peritoneum, omentum, and lymph nodes, even if they look normal, to detect microscopic disease.
In advanced cases (Stage III/IV), it is sometimes unclear whether a surgeon can successfully remove all the tumor. In these scenarios, a Diagnostic Laparoscopy is performed before the major open surgery. The surgeon inserts a camera through a small incision to visually inspect the abdominal cavity.
The goal is to assess “resectability.” If the tumor involves the root of the small bowel mesentery or encases the major blood vessels of the liver (porta hepatis), complete removal may be impossible or too dangerous. The Fagotti Score is a quantitative tool used during laparoscopy to assess disease burden across different quadrants. A high score indicates that primary surgery is unlikely to result in optimal tumor removal.
In these cases, the plan shifts from primary surgery to Neoadjuvant Chemotherapy (NACT). The patient receives chemotherapy first to shrink the tumors, followed by “Interval Debulking Surgery” after three to four cycles. This approach reduces surgical morbidity and increases the likelihood of achieving complete resection.
Send us all your questions or requests, and our expert team will assist you.
Clinical staging is an estimate based on physical exams and preoperative imaging. Surgical staging is the definitive stage determined after the surgeon has explored the abdomen, removed tissues, and the pathologist has examined them under a microscope. Treatment and prognosis are based on the surgical stage.
If a mass looks like early-stage cancer on imaging and is contained within the ovary, sticking a needle into it (biopsy) risks popping the cyst. This would spill cancer cells into the abdominal cavity, potentially advancing the stage from I to IC and worsening the prognosis. Therefore, the entire ovary is usually removed intact for diagnosis.
Ascites is the buildup of fluid in the abdomen. “Positive cytology” means that when this fluid was looked at under a microscope, cancer cells were found floating in it. This confirms that the cancer has spread beyond the ovary and into the peritoneal cavity, which affects the staging and treatment plan.
Yes. While CT scans are good at seeing large tumors and fluid, they struggle to see “miliary” disease—tiny, sand-like implants of cancer on the bowel or peritoneum that are less than a few millimeters in size. This is why surgical exploration is often needed to confirm the true extent of the disease.
This is a rare physical sign where ovarian cancer spreads to the umbilicus (belly button), causing a palpable lump. It is a sign of advanced, metastatic disease. It is named after a nurse who first recognized the connection between these umbilical nodules and intra-abdominal cancers.
Many people are surprised to learn that lower back pain can signal ovarian cancer. This is true if the pain is new, keeps coming back,
Abdominal bloating and a visibly larger stomach are common signs of ovarian cancer. These symptoms are often mistaken for regular digestive issues. At Liv Hospital,
Many people think that ovarian cancer always leads to vaginal bleeding. But, the truth is more nuanced. We’re here to tell you that bleeding isn’t
Many women feel like they need to go to the bathroom all the time. But, it’s often because of ovarian cysts. These growths can make
Ovarian cancer is often called a ‘silent killer’ because its symptoms are not obvious and it’s often diagnosed late. Early detection is key to better
Ovarian cancer is a major threat to women’s health. Some groups face much higher risks because of their genes, family history, and lifestyle. It’s key
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
